©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Discordant Expression of Osteoblast Markers in MC3T3-E1 Cells that Synthesize a High Turnover Matrix (*)

(Received for publication, December 29, 1995)

Richard J. Wenstrup (1)(§) John L. Fowlkes (3) David P. Witte (2) Jane B. Florer (1)

From the  (1)Divisions of Human Genetics and (2)Pathology, Cincinnati Children's Hospital, Cincinnati, Ohio 45229 and the (3)Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

To examine the autocrine effects that an organizing extracellular matrix has on osteoblast precursors, we created MC3T3-E1 cell lines that stably expressed pro-alpha1(I) collagen chains with a truncated triple helical domain. Cells that had incorporated the pro-alpha1(I) expression plasmid (pMG155) expressed shortened pro-alpha1(I) transcripts at high levels and efficiently secreted the expression gene products into culture media. Those cells lost over 30% of newly deposited collagenous matrix compared with virtually no loss in control cultures, and media from the abnormal cells had qualitative differences in matrix metalloprotinase production. Electron micrographs strongly suggested that type I collagen molecules containing the truncated pro-alpha1(I) chains dramatically interfered with collagen fibrillogenesis in newly forming osteoblast matrix. Abnormal collagen fibrillogenesis was also associated with altered characteristics of cellular differentiation in that abnormal cells displayed a delayed and attenuated increase in alkaline phosphatase activity. Surprisingly, synthesis of osteocalcin was more than 5-fold higher than control cultures. These findings demonstrate that osteoblasts require a normally structured collagenous matrix for up-regulation of alkaline phosphatase activity. However, in the presence of rapid turnover of osteoblast matrix, osteocalcin gene expression may be up-regulated in response to local signals by an unknown mechanism.


INTRODUCTION

Since techniques have become available for isolation and analysis of osteogenic precursor cells in culture(1, 2, 3, 4, 5, 6) there has been considerable interest in using these cell culture systems to understand the controlling events that regulate cessation of cell division and the initiation of cellular events that are the hallmarks of differentiation. In both primary osteoblasts (2, 3, 5, 7) and in the cloned mouse calvarial cell line MC3T3-E1(1, 4, 6) , a period of rapid cell division is followed by a transitional period that is characterized by deposition of an insoluble, type I collagen-rich extracellular matrix and an initial rise in alkaline phosphatase activity. Later, a third stage occurs, beginning approximately 2 weeks after plating, which is characterized by further increases in ALP activity, expression of osteocalcin, and mineral deposition.

There is both in vitro and in vivo evidence that deposition of a collagenous matrix in the transitional stage may regulate or at least have a permissive effect on the third stage of maturation of the osteoblast phenotype. Cultured osteoblast precursor cells grown in the absence of ascorbate, which is necessary for collagen deposition, fail to differentiate(2, 4, 6, 8, 9) ; a similar ascorbate-dependent effect has been observed in cultured chondrocytes(10, 11) . MC3T3-E1 cells grown in the presence of the collagen synthesis inhibitor 3,4-dehydroproline also fail to show bone-specific gene expression(4, 9, 12) . In addition, the hypothesis that type I collagen-cell interactions play a role in osteoblast maturation is supported by the analysis of bone tissue from individuals with the heritable disorder osteogenesis imperfecta whose cells secrete type I collagen that is either defective in structure and/or decreased in amount. Histological and biochemical studies of osteogenesis imperfecta bone have detected several abnormalities, including increased osteoblast number(13, 14) , decreased staining for alkaline phosphatase activity(15) , and decreased deposition of noncollagenous extracellular matrix proteins in bone(16, 17) .

Collectively, the above findings suggest that production of a collagen-rich extracellular matrix by bone cells is required for limitation of cell growth by some mechanism of feedback inhibition and for expression of alkaline phosphatase and possibly other osteoblast products that are associated with differentiated cells. Because it is not certain that ascorbate deprivation or proline analogs were completely specific in their effect on collagen matrix formation, we examined the osteoblast phenotype in clones of MC3T3-E1 cells that synthesize shortened pro-alpha1(I) chains encoded by a human pro-alpha1(I) minigene(18) . The shortened pro-alpha1(I) chains contain a normal carboxyl propeptide, a truncated triple helical domain, and most of the amino-terminal propeptide. Mice transgenic for this minigene have a brittle bone phenotype resembling human osteogenesis imperfecta(19, 20) . Type I collagen molecules containing this shortened pro-alpha1(I) chain are secreted into the extracellular matrix resulting in increased turnover of collagenous matrix and virtual destruction of the normal collagen fibrillar architecture. Cells expressing the minigene also have decreased alkaline phosphatase activity but significantly elevated expression of osteocalcin. These studies use a dominant negative collagen mutation to disrupt collagen fibrillogenesis in a more targeted way than ascorbate deprivation or chemical inhibition of collagen synthesis and provide evidence that normal collagen fibrillar architecture is a necessary prerequisite for transition of MC3T3-E1 cells from immature dividing cells to a more mature state.


EXPERIMENTAL PROCEDURES

Cell Culture

Stock cultures of MC3T3-E1 cells were grown in alpha-MEM (^1)(minimum essential medium containing 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 µg/ml)) with 5 mM beta-glycerol phosphate and 25 µg/ml of ascorbic acid. Cells were grown in a humidified atmosphere of 9% CO(2) and 90% air at 37 °C. Until the time of study, cells were subcultured every 3-5 days using 0.05% trypsin to achieve cell detachment. For studies characterizing the temporal sequence of osteoblast differentiation, 50,000 or 400,000 cells were plated into 35-mm diameter multiwell dishes or 100-mm plates and grown for periods ranging from 3 to 28 days. Cultures were fed with fresh media twice a week.

Assay of Cell Replication

At the completion of the incubation period, cells were harvested by removing the media, washing twice with phosphate-buffered saline, and treated for 5 min with 0.05% trypsin to achieve cell detachment. Cell number was determined at the various time points by direct counting with a hemocytometer.

Transfections

To create MC3T3-E1 cells that stably express a mutated type I collagen, subconfluent 100-mm dishes of cells were cotransfected with the expression plasmid pCDNA3 (Invitrogen Corp., San Diego, CA), which contains a neomycin resistance cassette, and pMG155 (18) (generously provided by Darwin Prockop, Thomas Jefferson University, Philadelphia, PA). pMG155 is a human pro-alpha1(I) minigene cloned into NotI/BamHI sites of Bluescript (Strategene Corp., La Jolla, CA); the insert contains 2.5 kilobases of promoter and genomic sequences that include exons 1-5 ligated to exons 47-52. Transfection was carried out overnight in serum-free alpha-MEM by lipid adsorption using Lipofectamine (Life Technologies, Inc.). Cells were then re-fed, and selection with 400 µg/ml G418 (Sigma) was initiated 48 h later. G418-resistant cells were grown to confluence and then plated at clonal density on 96-well plates. During clonal selection, cells were released from the dishes by trypsinization for 30 s every 3-4 days, and supplemented media were added to inactivate the trypsin. G418-resistant MC3T3-E1 clones were tested for pro-alpha1(I) minigene expression by Northern blot analysis of total cellular RNA using a human pro-alpha1(I) cDNA (21) as a probe.

Measurement of Collagenous Matrix

To quantify the accumulation of collagenous matrix deposited by MC3T3-E1 cells, colorimetric analysis of the hydroxyproline content of the cell layer was performed after hydrolysis of the cell layer with 6 N HCl(22) .

Analysis of Collagen Turnover

Twelve-day-old cultures were pulse-labeled with 200 µCi of [^3H]proline in serum-free medium supplemented with 50 µg/ml ascorbate and 5 mM beta-glycerol phosphate. After 48 h, labeling media were removed, and cultures were grown under normal conditions for 14 days longer (to day 28 after passage). Cell layers from duplicate dishes were collected on days 0, 4, 7, and 14 of chase and suspended in 1 ml of 6 N HCl and hydrolyzed for 24 h at 100 °C. Hydrolysates were dried under vacuum at 50 °C and reconstituted in 1 ml of 0.005 N HCl. [^3H]hydroxyproline was separated from [^3H]proline by paper chromatography; using a solvent mixture of butanol:acetic acid:H(2)O (6:1.5:1), 15-20 µl of sample, and 20 µg of each amino acid as standard, hydroxyproline and proline were detected as discrete spots by developing first with 0.2% isatin to identify proline and then with 2% p-dimethylaminobenzaldehyde to identify hydroxyproline. Hydroxyproline spots were cut out of the chromatogram, and ^3H-generated counts per minute were determined by scintillation counting.

Analysis of Conditioned Media by Gelatin-Substrate Zymography

Gelatin-substrate zymography was performed as described elsewhere, with modifications(1) . 45-µl aliquots of day 14 serum-free conditioned media from mutant and control clones of MC3T3-E1 cells were separated on 9.5% SDS-polyacrylamide gels containing 1 mg/ml gelatin (Sigma). Gels were electrophoresed for 1 h at 30 mA and then washed for 1 h at 4 °C in 2.5% Triton X-100. After extensive washing in distilled H(2)O, the gels were incubated in 50 mM Tris, 5 mM CaCl(2), pH 8.0, for 18 h at 37 °C on a rocking platform to activate gelatinases present in the samples. To visualize gelatinase activity present in the samples, gels were stained with Coomassie Blue, and gelatinase activity appeared as cleared areas within a dark blue background. The M(r) of the gelatinases was calculated based on their relative migration in relation to protein standards.

Assessment of Cell Maturation

Alkaline phosphatase enzyme activity was measured in cell layers by colorimetric assay as previously reported(23) .

Analysis of Proteins Secreted by MC3T3-E1 Cells

Media and cells were harvested separately as described previously into protease inhibitors(24) . Samples used for collagen analysis were dialyzed either against phosphate-buffered saline and directly analyzed or were dialyzed against 0.5 N acetic acid and lyophilized. Before proteins were harvested from media or cell layer at different time points after passages, serum was removed from media and the cells were re-fed for 16 h prior to harvest. Cell layers were harvested into guanidinium HCl. Harvested proteins were analyzed by electrophoresis on SDS-polyacrylamide gels and then electroblotted to a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). The membranes were reacted with polyclonal antisera to a peptide sequence from the carboxyl propeptide of human type I procollagen (LF41), a peptide sequence from murine decorin (LF113)(25) , murine bone osteonectin (LF23), or antisera to rat bone sialoprotein (LF87). These antisera were a generous gift from Dr. Larry W. Fisher (Bone Research Branch, NIDR, National Institutes of Health, Bethesda, MD). Equal loading of samples on the gel was insured by prior quantitation of total protein of sample by the method of Lowry(25) . Relative quantitation of blotted proteins was performed by scanning densitometry using the Ultrascan XL densitometer and Ultrascan XL software (Pharmacia Biotech Inc.). Quantitation of osteocalcin in culture media was performed by radioimmunoassay using reagents from Biomedical Technologies, Inc. (Stoughton, MA).

Measurement of Steady-state mRNAs from MC3T3-E1 Cells

In some experiments, total cellular RNA was isolated by guanidine isothiocyanate extraction (26) using TRIzol reagent (Life Technologies Inc.), and 10 µg was loaded on 1% agarose formaldehyde gels and separated by electrophoresis. RNA was transferred overnight onto GeneScreen Plus (Dupont) in 10 times SSPE buffer and baked at 80 °C for 2 h. Uniformity of RNA loading was determined by methylene blue staining of blots. The filters were hybridized to a P-labeled 600-base pair insert from plasmid Hf677, a human pro-alpha1(I) cDNA(21) , or to an approximately 500-base pair murine osteocalcin cDNA segment that was generated by reverse transcriptase-polymerase chain reaction from total cellular RNA of 21-day MC3T3-E1 cells grown under differentiating conditions, using primers designed from the human sequence(27) . The polymerase chain reaction product was confirmed to be osteocalcin by sequence analysis and comparison with a short segment of the mouse sequence(27) .

Electron Microscopy

MC3T3-E1 cells grown for 14 days under differentiating conditions were fixed by immersion in Karnovsky's solution containing 2.5% gluteraldehyde and 2% paraformaldehyde in 0.1 M sodium cachodylate buffer. Samples were then postfixed in 1% osmic acid, dehydrated through graded series of alcohols, and embedded in epon, which was polymerized at 60 °C for 36-48 h. Following polymerization the blocks were trimmed, and ultrathin sections were cut with a diamond knife using a Reichart Ultra-Cut E ultramicrotome. Sections were stabilized on a mesh copper grid post stained with lead citrate solution and viewed in the Zeiss 912 electron microscope.

Materials

2,3,4,5-^3[H]proline and [P]dCTP were from DuPont NEN. All culture materials, including alpha-MEM and fetal bovine serum, were obtained from Life Technologies, Inc.


RESULTS

We tested the ability of MC3T3-E1 cells to stably express a human pro-alpha1(I) minigene construct (pMG155) that contained genomic sequences including 2.5 kilobases of the pro-alpha1(I) promoter and exons 1-5 and 47-52(18) . Cells were transfected with pMG155 and the neo-containing expression plasmid pCDNA3. G418-resistant clones were analyzed by Northern blot analysis for expression of shortened pro-alpha1(I) transcripts (Fig. 1A), which were found in approximately one-half of G418-resistant clones. Immunoblot analysis of procollagens harvested from media and cell layer indicated that contrary to expectation, type I collagen molecules incorporating the minigene product are efficiently secreted from MC3T3-E1 cells rather than being degraded intracellularly (Fig. 1B). When several minigene expressing clones were analyzed, there was surprisingly little heterogeneity in the expression of the minigene product at the level of steady-state RNA or secreted protein; expression either approached that of the endogenous pro-alpha1(I) gene product or was undetectable even on prolonged exposures of Northern blots.


Figure 1: A, hybridization of a human pro-alpha1(I) collagen cDNA to 10 µg of total cellular RNA from untransfected MC3T3-E1 cells (lane 1) and cells from clone C3 (lane 2) and clone F6 (lane 3), which were transfected with pMG155 and pCDNA3 and selected with G418. G418-resistant clones either had easily detectable levels of expression of the minigene encoded in pMG155 (arrow) as in clone C3 or else had only the endogenous pro-alpha1(I) bands (brackets). B, immunoblot of samples from media (lanes 1-3) and cell layer (lanes 4-6) from untransfected MC3T3-E1 cells (lanes 1 and 4), clone C3 (lanes 2 and 5), or clone F6 (lanes 3 and 6). After electrophoretic separation, proteins were visualized with LF41, an antipeptide antiserum raised against the pro-alpha1(I) collagen C-propeptide that recognizes human and murine procollagen chains. In clone C3 but not clone F6 there is a low molecular weight band (arrow) detected with LF41. The low molecular weight band representing the shortened pro-alpha1(I) product of pMG155 was efficiently secreted into culture medium of clone C3 (lane 2).



When culture medium is supplemented with 50 µg/ml ascorbate and 5 mM beta-glycerol phosphate, MC3T3-E1 cells deposit a type I collagen-rich extracellular matrix that increases in a linear manner and is first measurable at the end of the first week of culture. Compared with cells from a representative control clone F6 (that had been simultaneously co-transfected with pCDNA3 and pMG155, selected with G418, and subsequently found not to express the minigene), cells from the minigene expressing clone C3 deposited approximately the same amount of collagen in culture dishes as measured by total hydroxyproline content (Fig. 2). To determine whether secretion of abnormal type I collagen molecules reduced the stability of collagen fibrils formed in the extracellular matrix, we performed pulse-chase studies in which cells were labeled for 48 h with [^3H]proline beginning at 12 days after plating. Rates of disappearance of [^3H]hydroxyproline from the insoluble cell layer were measured for a 2-week chase period. Cultures expressing the pro-alpha1(I) minigene retained only 66.3 ± 4.7% of newly deposited [^3H]hydroxyproline in osteoblast matrix during the 2-week chase compared with 97 ± 7.5% in control cultures (Fig. 3). Electron microscopy was performed to determine whether the relative instability of collagenous matrix produced by pro-alpha1(I) minigene-expressing cells could be related to abnormal collagen fibrillar structure. Images of collagen fibrils synthesized by control cells clearly show collagen fibrils recognizable by 67-nm periodicity that results from the nonintegral quarter stagger array of type I collagen monomers in fibrils; cells expressing the pro-alpha1(I) minigene synthesize collagen fibrils that were thinner and more disorganized and completely lacked the 67-nm pattern seen in controls (Fig. 4) In an attempt to determine whether the loss of [^3H]hydroxyproline from the cell layer could be explained by increased rates of collagen degradation, we examined the production of gelatinases in culture media from minigene-expressing cells by gelatin-substrate zymography. Compared with media from control F6 cells, media from two different minigene-expressing clones (C3 and C2) had higher rates of gelatinase activity overall and demonstrated much higher expression of an as yet uncharacterized 38-kDa gelatinase (Fig. 5). In spite of the higher turnover of type I collagen in the matrix, there was no evidence of compensatory up-regulation of the endogenous pro-alpha1(I) collagen gene (Fig. 1, A and B). Secretion of osteonectin, decorin, and bone sialoprotein, three other proteins that are deposited into osteoblast matrix and are thought to be bound to or adjacent to collagen fibrils (28, 29, 30, 31, 32) , was likewise not increased over control (Fig. 6).


Figure 2: Determination of hydroxyproline content of the cell layers of C3 cells (black, expressing the procollagen minigene) and control F6 cells (hatched). Cell layers were harvested, and proteins were hydrolyzed with 6 N HCl prior to spectrophometric analysis(22) . Error bars reflect standard error of the mean, n = 3.




Figure 3: Percentage of [^3H]hydroxyproline retained in the cell layer of C3 cells (black, expressing the pro-alpha1(I) collagen minigene) and F6 control cells (hatched) after labeling with [^3H]proline for 48 h at days 12-14 after passage followed by chase with unlabeled media. Retention value was arbitrarily set at 100% at day 0 of chase. Error bars reflect standard error of the mean, n = 5.




Figure 4: Electron micrographs, at times 60,000, of the cell layer of control cells (clone F6, left) or cells that expressed the pro-alpha1(I) minigene (clone C3, right). The 67-nm periodicity apparent in the control collagen fibrils is absent in fibrils synthesized by abnormal cells.




Figure 5: Gelatinases produced by mutant and control MC3T3-E1 clones. Conditioned media from mutant osteoblast clones (C3, lanes 1 and 2; and C2, lanes 3 and 4) or a control clone (F6, lanes 5 and 6) were analyzed by gelatin-substrate zymography. The 38-kDa gelatinase produced at high levels by mutant osteoblasts is denoted by the arrow.




Figure 6: Immunoblots of samples from media of clone C3 and clone F6 in which immobilized proteins harvested at days 8 and 21 after passage were reacted with LF113, antiserum to murine decorin core protein (arrow), before and after digestion of saccharides with chondroitinase (top), with LF 23, antiserum to murine osteonectin (middle), or with LF87, antiserum to rat bone sialoprotein (bottom). There were no significant differences in band density between the control F6 and the pro-alpha(I) collagen minigene expressing C3 cells at either time point.



We then examined alkaline phosphatase activity in control and minigene-expressing cells to determine whether abnormal collagen fibrillogenesis had an effect on osteoblast differentiation. In the presence of ascorbate and 5 mM beta-glycerol phosphate, MC3T3-E1 cells in culture show a time-dependent decrease in cell growth and a subsequent increase in alkaline phosphatase activity beginning about 9 or 10 days after plating(4, 6) . There was significant clonal variation in both basal and maximal levels of alkaline phosphatase activity found in all clones, but the level of maximal activity (attained between 21 and 28 days after plating) correlated with basal activity, which was constant between days 2 and 8 (Fig. 7). Four control clones had maximal alkaline phosphatase activity that was a mean 6.9 ± 1.5-fold increase over basal activity, compared with a mean -fold increase of 2.2 ± 0.47 in four minigene-expressing clones.


Figure 7: Basal and maximal levels of alkaline phosphatase activity, expressed in µmol of p-nitrophenol produced per min per cell, of four minigene-expressing MC3T3-E1 cell clones (open symbols) and four control clones (closed symbols). Mean -fold increase in control clones was 6.9 ± 1.5 over basal activity, compared with 2.2 ± 0.47 in four minigene-expressing clones.



To determine whether the abnormal collagenous matrix also attenuated expression of osteocalcin, another commonly used marker of osteoblast differentiation, we then measured secretion of osteocalcin by radioimmunoassay using antisera to mouse osteocalcin. Surprisingly, cells from the minigene-expressing clone C3 had five to six times more osteocalcin than control in culture media at days 14, 21, and 28 after plating (Fig. 8A). Because we were concerned that the elevated levels of osteocalcin might merely reflect osteocalcin released into culture media from the high turnover matrix rather than newly synthesized protein, we compared steady-state osteocalcin mRNA levels as well; differences in mRNA levels between control and abnormal cells either reflected or exceeded differences found in secreted osteocalcin measured by radioimmunoassay (Fig. 8B). To determine whether the increase in osteocalcin synthesis and steady-state RNA resulted from the abnormal matrix produced by the presence of truncated collagen chains in the matrix or was merely due to clonal variation in osteocalcin expression in MC3T3-E1 cells, steady-state osteocalcin mRNAs were examined by scanning densitometry of Northern blots in a total of four minigene-expressing and four control MC3T3-E1 clones. While there was some clone-to-clone variation in osteocalcin gene expression, clear differences in the pattern of osteocalcin expression were apparent (Fig. 9); much more osteocalcin mRNA was present in minigene-expressing clones, particularly at days 14 and 21 after passage. By day 28, consistent differences in steady-state levels of osteocalcin mRNA between minigene-expressing and nonexpressing clones were less apparent (data not shown).


Figure 8: A, osteocalcin concentration measured by radioimmunoassay at 14, 21, and 28 days after passage in culture media of C3 cells (black, expressing the pro-alpha1(I) collagen minigene) and F6 control cells (hatched). Error bars reflect standard error of the mean, n = 3. B, hybridization of a murine osteocalcin cDNA to 10 µg of total cellular RNA harvested from clone C3 (M), and the control clone F6 (C) at days 3, 7, 11, 14, and 28 after plating. The approximately 0.6-kilobase osteocalcin message (arrow) was detected beginning at day 7 in C3 cells and at day 14 in F6 control cells.




Figure 9: Results of scanning densitometric measurement of osteocalcin steady-state mRNA in four minigene expressing (open symbols) and nonexpressing (closed symbols) clones of MC3T3-E1 cells. There were easily apparent differences at days 14 and 21. By day 28, consistent differences in steady-state levels of osteocalcin mRNA between minigene-expressing and nonexpressing clones were less apparent.




DISCUSSION

Expression of a dominant negative type I collagen mutation in the murine calvarial osteoblast cell line MC3T3-E1 resulted in deposition of a type I collagen matrix that has relatively high rates of turnover compared with control cultures. Deposition of the abnormal matrix resulted in suppression of one marker of osteoblast differentiation (alkaline phosphatase activity) and a significant increase in another (osteocalcin secretion). There was no compensatory up-regulation of the expression of other bone matrix proteins including type I collagen, decorin, bone sialoprotein, and osteonectin.

The human pro-alpha1(I) minigene product expressed by the pMG155 expression plasmid contains an intact carboxyl propeptide required for molecular assembly and 23 uninterrupted Gly-X-Y triplets of the adjacent triple helical domain; it would therefore be expected to co-assemble with wild-type mouse pro-alpha chains, and SDS-polyacrylamide gel electrophoresis under nonreducing conditions showed that the shortened pro-alpha1(I) chains were not secreted as monomers (data not shown). The turnover of [^3H]hydroxyproline from the collagen matrix is due primarily to loss of type I collagen molecules having either one or both wild-type pro-alpha1(I) chains, since there are very few Y-positioned prolines available for prolyl hydroxylation in the truncated triple helix of the minigene product(18) . Furthermore, the increased matrix turnover may be enhanced by alterations in matrix metalloproteinase production by cells producing the minigene product. The reason why the collagenous matrix deposition by 21 days is not much lower in cells secreting the truncated pro-alpha1(I) chains is not entirely clear but may be due to the fact that there were higher cell numbers in the minigene-expressing clones that were measured for hydroxyproline deposition compared with the control clones.

These experiments, which use a dominant negative type I collagen mutation to effect a targeted disruption of collagen fibrillogenesis, augment previous in vitro studies of collagen-osteoblast interaction in two ways. First, they lend support to the theory that suppression of osteoblast characteristics by ascorbate deprivation (2, 4, 6, 9) or by the addition of proline analogs (4, 9) is due at least in part to the inhibition of collagen deposition. Second, these data indicate that the increase in alkaline phosphatase activity associated with osteoblast differentiation depends not only on the overall quantity of collagen deposited by also on normal collagen structure.

An unanticipated result of these studies was that the relative instability and abnormal structure of the extracellular matrix in cells expressing the pro-alpha1(I) minigene was associated with a dramatic increase in osteocalcin gene expression, particularly in earlier stages of cellular differentiation. This elevation of osteocalcin expression was in contrast to what was observed in studies in which collagen deposition was merely reduced in quantity by ascorbate deprivation or by collagen synthesis inhibitors; in the latter cases, both alkaline phosphatase activity and osteocalcin gene expression failed to increase during prolonged osteoblast cultures(4, 9) .

The stimulation of osteocalcin gene expression in the presence of a rapid matrix turnover suggests a more complex mechanism for its regulation. Basal expression of osteocalcin associated with cellular differentiation (33, 34) is detectable after about 14 days in MC3T3-E1 cells cultured under differentiating conditions (Fig. 8B); in cells that expressed truncated pro-alpha1(I) chains, osteocalcin gene expression began at day 7, shortly after collagen deposition is detectable but before the expected onset of basal expression that is associated with cellular differentiation. It is also evident that the up-regulation of osteocalcin expression occurred through a mechanism distinct from that which is initiated by pharmacological doses of 1,25-dihydroxycholicalciferol (vitamin D); however, our experiments do not exclude the possibility that trace amounts of vitamin D present in bovine serum had a permissive effect on osteocalcin expression in cells making an abnormal matrix.

It appeared that the osteocalcin gene responded differently to high rates of turnover than the genes coding for other components of the extracellular matrix (reviewed in (35) ). For example, type I collagen, decorin, and osteonectin were not increased, even in longer cultures. Osteocalcin differs from those matrix components in that it is thought to play a role in bone turnover(36, 37, 38) . The data contained in this report suggest that osteocalcin may be regulated by factors released from osteoblast matrix undergoing high rates of turnover. The identity of that factor or factors, the signal pathway that might be used, and target sequences on the osteocalcin promoter are the objects of further study. It is interesting to note that the abnormal matrix did not induce an increase in the secretion of bone sialoprotein, an approximately 80-kDa protein found in skeletal tissues. Its function is not known, but it has been hypothesized to play a role in attachment of osteoclasts to bone because it contains an RGD sequence and supports the attachment of osteoclasts in vitro, perhaps through ligation of the alpha(v)beta(3) integrin(39) .

The mechanism by which deposition of a collagen-rich osteoblast matrix facilitates the transition from immature, rapidly dividing preosteoblasts to differentiated cells is unknown. Type I collagen may act directly on cellular receptors, or it might be merely required as a latticework for other matrix proteins which themselves interact directly with cells. It is unclear whether signals initiated by insoluble matrix molecules act directly to promote osteoblast-specific gene expression or whether cell-matrix interactions have indirect effects by which they might change in the repertoire of cellular receptors for hormones or cytokines present in the extracellular matrix (40, 41) . These studies suggest a need for better understanding of extracellular matrix receptors and downstream signaling pathways by which matrix components modulate gene expression in differentiating osteoblasts.

Although stable incorporation of informative genes in MC3T3-E1 cells is a powerful means to alter the extracellular environment of osteoblastic precursor cells, the clonal selection required for this strategy to work allows for the possibility that observed differences in osteoblast characteristics may be due to clonal variation rather than a response to the altered extracellular matrix.

In these studies, several steps were taken to minimize the effect of clonal drift. All control clones were chosen from cells that had been transfected with both pCDNA3 and pMG155 and had undergone clonal selection with G418 but did not express the pro-alpha1(I) minigene. Second, all clones undergoing selection were ``passed'' by brief trypsinization in the dishes twice a week to maintain characteristics of differentiated osteoblasts. Finally, several minigene-expressing and nonexpressing clones were examined to confirm that discordant expression of osteocalcin and alkaline phosphatase was a characteristic of clones that expressed the pro-alpha1(I) minigene.


FOOTNOTES

*
These studies were supported by National Institutes of Health Grants AR40586 and DK02276 and a grant from the Lucille Markey Trust. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Division of Human Genetics, TCHRF Room 1033, 3333 Burnet Ave., Cincinnati, OH 45229. Tel.: 513-559-4471; Fax: 513-559-4373; wenstrrj{at}ucbeh.san.uc.edu.

(^1)
The abbreviation used is: MEM, minimal essential medium.


ACKNOWLEDGEMENTS

We thank Dr. Larry Fisher for providing several antibodies as well as helpful advice on optimal conditions for their use.


REFERENCES

  1. Sudo, H., Kodama, H., Amagai, Y., Yamamoto, S., and Kasai, S. (1983) J. Cell Biol. 96, 191-198 [Abstract]
  2. Gerstenfeld, L. C., Chipman, S. D., Glowacki, J., and Lian, J. B. (1987) Dev. Biol. 122, 49-60 [Medline] [Order article via Infotrieve]
  3. Aronow, M. A., Gerstenfeld, L. C., Owen, T, A., Tassinari, M. S., Stein, G. S., and Lian, J. B. (1990) J. Cell. Physiol. 143, 213-221 [Medline] [Order article via Infotrieve]
  4. Franceschi, R. T., and Iyer, B. S. (1992) J. Bone Miner. Res. 7, 235-246 [Medline] [Order article via Infotrieve]
  5. Gronowicz, G. R., Woodiel, N., McCarthy, M., and Raisz, L. G. (1989) J. Bone Miner. Res. 4, 313-324 [Medline] [Order article via Infotrieve]
  6. Quarles, L. D., Yohay, D. A., Lever, L. W., Caton, R., and Wenstrup, R. J. (1992) J. Bone Miner. Res. 7, 683-692 [Medline] [Order article via Infotrieve]
  7. Lian, J. B., and Stein, G. S. (1992) Crit. Rev. Oral Biol. Med. 3, 269-305 [Abstract]
  8. Gerstenfeld, L. C., Chipman, S. D., Kelly, C. M., Hodgens, K. J., Lee, D. D., and Landis, W. J. (1988) J. Cell Biol. 106, 979-989 [Abstract]
  9. Franceschi, R. T., Iyer, B. S., and Cui, Y. (1994) J. Bone Miner. Res. 9, 843-854 [Medline] [Order article via Infotrieve]
  10. Leboy, P. S., Vaias, L., Uschmann, B., Golub, E., Adams, S. L., and Pacifici, M. (1989) J. Biol. Chem. 264, 17281-17286 [Abstract/Free Full Text]
  11. Wu, N. Y., Sauer, G. R., Gene, B. R., and Wuthier, R. E (1989) J. Biol. Chem. 264, 21346-21355 [Abstract/Free Full Text]
  12. Uitto, J., and Prockop, D. J. (1975) in Collagen Metabolism in the Liver (Popper, H., and Becker, K., eds) pp. 139-148, Stratton, New York
  13. Baron, R., Gertner, J. M., Lang, R., and Vignery, A. (1983) Pediatr. Res. 17, 204-207 [Abstract]
  14. Ste-Marie, L. G., Charhon, S., Edouard, C., Chapuy, M. C., and Meunier, P. J. (1984) J. Clin. Pathol. 37, 1081-1089 [Abstract]
  15. Doty, S. B., and Mathews, R. S. (1971) Clin. Orthop. Relat. Res. 80, 191-201 [Medline] [Order article via Infotrieve]
  16. Termine, J. D., Gerhon Robey, P., Fisher, L. W., Shimokawam, H., Drum, M. A., Conn, K. M., Hawkins, G. R., Cruz, J. B., and Thompson, K. G. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 2213-2217 [Abstract]
  17. Vetter, U., Fisher, L. W., Mintz, K. P., Kopp, J. B., Tuross, N., Termine, J. D., and Robey, P. G. (1991) J. Bone Miner. Res. 6, 501-505 [Medline] [Order article via Infotrieve]
  18. Olsen, A. S., Geddis, A. E., and Prockop, D. J. (1991) J. Biol. Chem. 266, 1117-1121 [Abstract/Free Full Text]
  19. Pereira, R., Khillan, J. S., Helminen, H. J., Hume, E. L., and Prockop, D. J. (1993) J. Clin. Invest. 91, 709-716 [Medline] [Order article via Infotrieve]
  20. Helminen, H. J., Kiraly, K., Pelttari, A., Tammi, M. I., Vandenberg, P., Pereira, R., Dhulipala, R., Khillan, J. S., Ala-Kokko, L., and Hume, E. L. (1993) J. Clin. Invest. 92, 582-595 [Medline] [Order article via Infotrieve]
  21. Bernard, M. P., Chu, M., Myers, J. C., Ramirez, F., Eikenberry, E. F., and Prockop, D. J. (1983) Biochemistry 22, 5213-5223 [Medline] [Order article via Infotrieve]
  22. Berg, R. A. (1982) Methods Enzymol. 82, 372-398 [Medline] [Order article via Infotrieve]
  23. Quarles, L. D., Wenstrup, R. J., Castillo, S. A., and Drezner, M. K. (1991) Endocrinology 128, 3144-3151 [Abstract]
  24. Bonadio, J., Holbrook, K. A., Gelinas, R. E., Jacob, J., and Byers, P. H. (1985) J. Biol. Chem. 260, 1734-1742 [Abstract]
  25. Lowry, O. H., Rosebrough, N. J., Farr, A. J., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  26. Chomczynski, P., and Sacchi, N. (1987) Anal. Chem. 162, 156-159
  27. Celeste, A. J., Buecker, J. L., Kriz, R., Wang, E. A., and Wozney, J. M. (1986) EMBO J. 5, 1885-1890 [Abstract]
  28. Termine, J. D., Kleinman, H. K., Whitson, S. W., Conn, K. M., McGarvey, M. L., and Martin, G. R. (1981) Cell 26, 99-105 [Medline] [Order article via Infotrieve]
  29. Bianco, P., Fisher, L. W., Young, M. F., Termine, H. D., and Robey, P. G. (1990) J. Histochem. Cytochem. 38, 1549-1563 [Abstract]
  30. Oldberg, A., Franzen, A., and Heinegard, D. (1988) J. Biol. Chem. 263, 19430-19432 [Abstract/Free Full Text]
  31. Oldberg, A., Franzen, A., Heinegard, D., Pierschbacher, M., and Ruoslahti, E. (1988) J. Biol. Chem. 263, 19433-19436 [Abstract/Free Full Text]
  32. Fujisawa, R., and Kuboki, Y. (1992) Calcif. Tissue Int. 51, 438-442 [Medline] [Order article via Infotrieve]
  33. Owen, T. A., Bortell, R., Shalhoub, V., Heinrichs, A., Stein, J. L., Stein, G. S., and Lian, J. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1503-1507 [Abstract]
  34. Owen, T. A., Bortell, R., Yocum, S. A., Smock, S. L., Zhang, M., Abate, C., Shalhoub, V., Aronin, N., Wright, K. L., and van Wijnen, A. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9990-9994 [Abstract]
  35. Robey, P. G., Fedarko, N. S., Hefferan, T. E., Bianco, P., Vetter, U. K., Grzesik, W., Friedenstein, A., Van der Pluijm, G., Mintz, K. P., and Young, M. F. (1993) J. Bone Miner. Res. 8, (suppl. 2) S483-S487
  36. Glowacki, J., Rey, C., Cox, K., and Lian, J. (1989) Connect Tissue Res. 20, 121-129 [Medline] [Order article via Infotrieve]
  37. Glowacki, J., and Lian, J. B. (1987) Cell Differ. 21, 247-254 [CrossRef][Medline] [Order article via Infotrieve]
  38. Desbois, C., Hagihara, K., Pinero, G., Boyce, B., Bonadio, J., Tseng, K. F., Goulet, R., Goldstein, S., Loyer, E., Bradley, A., and Karsenty, G. (1995) J. Bone Miner. Res. 10, S139 [Medline] [Order article via Infotrieve] (abstr.)
  39. Miyauchi, A., Alvarez, J., Greenfield, E. M., Teti, A., Grano, M., Colucci, S., Zambonin-Zallone, A., Ross, F. P., Teitelbaum, S. L., Cheresh, D., and Hruska, K. A. (1991) J. Biol. Chem. 266, 20369-20374 [Abstract/Free Full Text]
  40. Ikeda, K., Michelangeli, V. P., Martin, T. J., and Findlay, D. M. (1993) J. Cell. Physiol. 156, 130-137 [Medline] [Order article via Infotrieve]
  41. Takeuchi, Y., Fukumoto, S., Nakayama, K., and Matsumoto, T. (1994) J. Bone Miner. Res. 9, S126

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.